1.	Phase II Study of Monoclonal Antibody 3F8 with Sargramostim (GM-CSF) in Patients with Advanced Neuroblastoma Phase: Phase II Type: Treatment Status: Closed Age: 2 to 21 Sponsor: Other Protocol IDs: MSKCC-94018, NCI-V94-0416, NCT00002560
2.	Phase II Study of Intensive Multimodality Therapy for Poor Risk Neuroblastoma: Sequential Cyclophosphamide, Doxorubicin, and Vincristine Along With Cisplatin and Etoposide, External-Beam Radiotherapy, and Radioimmunotherapy With Iodoine I 131 Monoclonal Antibody (MOAB 3F8) Followed by Autologous Bone Marrow Transplantation and Immunotherapy With MOAB 3F8 Phase: Phase II Type: Treatment Status: Closed Age: over 1 at diagnosis Sponsor: Other Protocol IDs: MSKCC-94011A1, MSKCC-FDR001041, NCI-V95-0622, NCT00002634
3.	Phase II Study of Monoclonal Antibody 3F8, Etoposide, and Isotretinoin in Patients With High-Risk Neuroblastoma Phase: Phase II Type: Treatment Status: Closed Age: Not specified Sponsor: NCI Protocol IDs: MSKCC-IRB-99033, NCI-G99-1599, NCT00004110
4.	Phase II Study of Multimodality Therapy Comprising Dose-Intensive Induction Chemotherapy, Monoclonal Antibody 3F8, Surgery, Myeloablative Chemotherapy, Autologous or Syngeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation, Radiotherapy, and Isotretinoin in Patients With Advanced Neuroblastoma Phase: Phase II Type: Treatment Status: Closed Age: 50 and under Sponsor: NCI Protocol IDs: MSKCC-00065, NCI-G02-2083, NCT00040872
5.	Phase II Study of Antiganglioside GD2-Specific Mouse MOAB 3F8 in Patients with Neuroblastoma in Early Relapse (Summary Last Modified 08/91) Phase: Phase II Type: Treatment Status: Completed Age: under 18 Sponsor: Protocol IDs: MSKCC-87059, NCI-V88-0353
6.	Phase II Study of Adjuvant Therapy with Antiganglioside GD2-Specific Mouse Monoclonal Antibody 3F8 for Metastatic Neuroblastoma in Second Remission Phase: Phase II Type: Treatment Status: Closed Age: under 18 Sponsor: Other Protocol IDs: MSKCC-87118, NCI-V88-0357, NCT00002458
7.	Phase II Study of the N6 Regimen Involving Intensive Chemotherapy with CAV (CTX/DOX/VCR) and PVP (VP-16/CDDP) with Adjuvant MOAB 3F8, plus Surgery and Radiotherapy as Appropriate, in Patients with Poor-Risk Neuroblastoma (Summary Last Modified 01/91) Phase: Phase II Type: Treatment Status: Closed Age: any age Sponsor: Protocol IDs: MSKCC-89175A2, NCI-V90-0023
8.	Phase II Study of Monoclonal Antibody 3F8, Beta-Glucan, Isotretinoin and Sargramostim (GM-CSF) in Patients With High-Risk Refractory Neuroblastoma Phase: Phase II Type: Treatment Status: Completed Age: Any age Sponsor: NCI Protocol IDs: MSKCC-04050, NCT00089258
9.	Phase I Study of beta-Glucan and Monoclonal Antibody 3F8 in Patients With Metastatic Neuroblastoma Phase: Phase I Type: Treatment Status: Closed Age: Under 50 Sponsor: NCI Protocol IDs: MSKCC-01075, NCI-G02-2067, NCT00037011
10.	Phase I Study of Anti-GD2 (3F8) and Anti-GD3 (R24) Mouse Monoclonal Antibodies in Patients with Metastatic Melanoma or Soft Tissue Sarcoma (Summary Last Modified 08/88) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: MSKCC-86066, NCI-V88-0387
11.	Phase I Evaluation of 131I-Labeled Anti-Ganglioside GD2 Mouse Monoclonal Antibody 3F8 as Radiotherapy in Patients with Refractory Neuroblastoma and GD2 Positive Tumors (Summary Last Modified 11/90) Phase: Phase I Type: Treatment Status: Closed Age: over 1 Sponsor: Protocol IDs: MSKCC-87141, NCI-V88-0459
12.	Phase I Pilot Study of In Vitro Purging of Marrow with Anti-Ganglioside GD2 Murine Monoclonal Antibody 3F8 in Patients with Neuroblastoma (Summary Last Modified 06/94) Phase: Phase I Type: Treatment Status: Closed Age: children Sponsor: Protocol IDs: MSKCC-89105, NCI-V89-0294